BioSpace

@gossamerbio will cut about 48% of its workforce, while BiomX has disclosed it laid off a “significant” portion of its staff in December. Learn more in our layoff tracker. #layoffs #biopharma #biospace hubs.li/Q047Jq0r0

A spokesperson for the Department of Health and Human Services refuted the claim, made Thursday on social media by ACIP Vice Chair Robert Malone, calling it “baseless speculation.” #HHS #government #biospace hubs.li/Q047HHyf0

Biotech, in particular companies that are pre-commercial with a longer-duration risk profile, could be great investments as Operation Epic Fury rolls on, according to a Truist Securities analysis. #biotech #investments #biospace hubs.li/Q047HKq20

At its peak, Imcivree’s sales in hypothalamic obesity could reach over $2 billion worldwide, according to analysts at Stifel. #obesity #pharma #biospace hubs.li/Q047HDqY0

Aside from the $2 billion upfront payment, Novartis is also putting up to $1 billion on the line in milestones for Synnovation Therapeutics’ pan-mutant-selective PI3Kα blocker. #pharma #biospace hubs.li/Q047HKhz0

The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was hobbled by manufacturing concerns at a Novo Nordisk facility last year but is now nearing a potential resolution. #pharma #biospace hubs.li/Q047HwyC0

With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months. #vouchers #wegovy #biospace hubs.li/Q047HjrK0

The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China. #manufacturing #biospace hubs.li/Q047Hkdc0

Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether the agency will agree to approve them is still unknown. #FDA #regulatory #biospace hubs.li/Q047Hjm20

Eli Lilly’s retatrutide could present a “differentiated option” for patients with type 2 diabetes who want to control their blood sugar and achieve maximal weight loss, according to analysts at BMO Capital Markets. #diabetes #pharma #biospace hubs.li/Q047x_WS0

Among those who connected salary increases to swapping out employers, 75% saw pay rise by at least 6%, and the most often cited increase was 10%, according to our just-released salary report. #salaries #salaryreport #biopharma #biospace hubs.li/Q047xT2p0

Recruiters can play a significant role in biopharma professionals getting hired, especially in an employer-driven job market. However, when working with them, candidates need to avoid making six key mistakes, from waiting too long to ask for help to prematurely contacting hiring companies. #recruiters #biopharma #biospace hubs.li/Q047xF1_0

Looking for a clinical job? Check out our list of 11 companies hiring life sciences professionals like you. #nowhiring #biopharma #biospace hubs.li/Q047xH8r0

Gossamer Bio reported last month that its only late-stage candidate failed a Phase 3 study in pulmonary arterial hypertension, casting doubt on the asset’s future prospects. #layoffs #biospace hubs.li/Q047wRBf0

Prime biotech buyout targets such as Revolution Medicines and BioCryst Pharmaceuticals have recently found themselves in the middle of acquisition rumors—though no deals have panned out so far. #biotech #pharma #biospace hubs.li/Q047wF220

Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether the agency will agree to approve them is still unknown. #FDA #pharma #biospace hubs.li/Q047y7g_0

🚨 Decision Day surprises? Hard pass. If you’re navigating the FDA pathway, the last thing you want is unexpected feedback at the finish line. Join our upcoming webinar: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises and learn how to stay aligned early, communicate strategically, and move forward with confidence. Register now: hubs.li/Q045p6yD0 #biotech #pharma #FDA #regulatory #biospace

The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China. #manufacturing #celltherapy #CART #biospace hubs.li/Q047y8xG0

A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns surface about the politicization of the agency. #FDA #vaccines #pharma #biospace hubs.li/Q047wPWv0

BioSpace‘s 2026 U.S. Life Sciences Salary Report delivers a comprehensive look at how salaries, bonuses and benefits evolved over the past year amid ongoing economic pressure and workforce recalibration. It uncovers not just what people are earning, but how they’re thinking about compensation, career moves and total rewards in 2026. #jobtrends #careers #lifesciences #report #biospace hubs.li/Q047wBvT0